Pacific Biosciences of California, Inc.
NASDAQ:PACB
1.9 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 200.521 | 128.304 | 130.513 | 78.893 | 90.891 | 78.626 | 93.468 | 90.714 | 92.782 | 60.594 | 28.181 | 25.983 | 33.863 | 1.674 | 0.135 | 0.901 | 2.163 |
| Cost of Revenue
| 160.176 | 79.269 | 71.653 | 46.327 | 56.315 | 53.53 | 58.809 | 46.554 | 39.332 | 37.192 | 21.762 | 25.043 | 20.829 | 0 | 0 | 0 | 0 |
| Gross Profit
| 40.345 | 49.035 | 58.86 | 32.566 | 34.576 | 25.096 | 34.659 | 44.16 | 53.45 | 23.402 | 6.419 | 0.94 | 13.034 | 1.674 | 0.135 | 0.901 | 2.163 |
| Gross Profit Ratio
| 0.201 | 0.382 | 0.451 | 0.413 | 0.38 | 0.319 | 0.371 | 0.487 | 0.576 | 0.386 | 0.228 | 0.036 | 0.385 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 187.17 | 193 | 112.899 | 64.152 | 59.63 | 62.594 | 65.324 | 67.617 | 60.44 | 48.23 | 45.217 | 47.623 | 76.08 | 111.821 | 75.879 | 37.997 | 19.216 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 63.489 | 59.119 | 47.787 | 45.187 | 38.026 | 38.745 | 47.655 | 46.71 | 30.087 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 163.54 | 160.854 | 124.124 | 72.799 | 75.491 | 63.489 | 59.119 | 47.787 | 45.187 | 38.026 | 38.745 | 47.655 | 46.71 | 30.087 | 12.326 | 7.713 | 6.338 |
| Other Expenses
| 32.684 | 7.638 | 0.093 | 2.055 | 1.022 | 0.848 | 0.516 | 0.103 | 0.364 | -0.478 | 0.728 | -0.127 | 0 | -0.104 | -0.084 | -0.102 | -0.067 |
| Operating Expenses
| 350.71 | 353.854 | 237.023 | 136.951 | 135.121 | 126.083 | 124.443 | 115.404 | 105.627 | 86.256 | 83.962 | 95.278 | 122.79 | 141.908 | 88.205 | 45.71 | 25.554 |
| Operating Income
| -310.365 | -304.819 | -178.163 | -104.385 | -100.545 | -100.987 | -89.784 | -71.244 | -29.134 | -62.854 | -77.543 | -94.338 | -109.756 | -140.234 | -88.07 | -44.809 | -23.391 |
| Operating Income Ratio
| -1.548 | -2.376 | -1.365 | -1.323 | -1.106 | -1.284 | -0.961 | -0.785 | -0.314 | -1.037 | -2.752 | -3.631 | -3.241 | -83.772 | -652.37 | -49.733 | -10.814 |
| Total Other Income Expenses Net
| -7.794 | -9.429 | -96.709 | 133.788 | 16.411 | 0.848 | 0.516 | 0.103 | 23.407 | -0.478 | 0.728 | -0.127 | 0.368 | -0.104 | -0.084 | -0.102 | -0.067 |
| Income Before Tax
| -318.159 | -314.248 | -274.872 | 29.403 | -84.134 | -102.562 | -92.189 | -74.375 | -31.696 | -66.16 | -79.293 | -94.465 | -109.388 | -140.166 | -87.703 | -43.754 | -21.518 |
| Income Before Tax Ratio
| -1.587 | -2.449 | -2.106 | 0.373 | -0.926 | -1.304 | -0.986 | -0.82 | -0.342 | -1.092 | -2.814 | -3.636 | -3.23 | -83.731 | -649.652 | -48.562 | -9.948 |
| Income Tax Expense
| -11.424 | -17.318 | -93.649 | -6.982 | -6.315 | 0.848 | -5.005 | 3.337 | -0.387 | 2.35 | 3.206 | 0 | -0.368 | -0.172 | -0.451 | -1.157 | -1.94 |
| Net Income
| -306.735 | -296.93 | -181.223 | 29.403 | -77.819 | -102.562 | -92.189 | -74.375 | -31.696 | -66.16 | -79.293 | -94.465 | -109.388 | -140.166 | -87.703 | -43.754 | -21.518 |
| Net Income Ratio
| -1.53 | -2.314 | -1.389 | 0.373 | -0.856 | -1.304 | -0.986 | -0.82 | -0.342 | -1.092 | -2.814 | -3.636 | -3.23 | -83.731 | -649.652 | -48.562 | -9.948 |
| EPS
| -1.21 | -1.32 | -0.89 | 0.18 | -0.51 | -0.76 | -0.87 | -0.83 | -0.42 | -0.94 | -1.26 | -1.69 | -2.03 | -14.1 | -113.33 | -56.54 | -0.78 |
| EPS Diluted
| -1.21 | -1.32 | -0.89 | 0.17 | -0.51 | -0.76 | -0.87 | -0.83 | -0.42 | -0.94 | -1.26 | -1.69 | -2.03 | -14.1 | -113.33 | -56.54 | -0.78 |
| EBITDA
| -277.674 | -297.181 | -178.07 | -102.33 | -99.523 | -100.139 | -89.268 | -67.266 | -51.813 | -59.111 | -71.167 | -87.689 | -104.321 | -135.074 | -83.966 | -41.822 | -21.814 |
| EBITDA Ratio
| -1.385 | -2.316 | -1.364 | -1.297 | -1.095 | -1.274 | -0.955 | -0.742 | -0.558 | -0.976 | -2.525 | -3.375 | -3.081 | -80.689 | -621.97 | -46.417 | -10.085 |